1344029-42-0

Basic information

• Product Name: 1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline hydrochloride
• Synonyms: 1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline hydrochloride
• CAS NO: 1344029-42-0
• Molecular Weight: 427.03
• Mol File: 1344029-42-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline hydrochloride(1344029-42-0)
• EPA Substance Registry System: 1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline hydrochloride(1344029-42-0)

Safety Data

• Hazardous Substances Data: 1344029-42-0(Hazardous Substances Data)

Upstream product

• 64-04-0 phenethylamine 
• 71022-62-3 2-methyl-N-(2′-phenethyl)-propionamide 
• 1344029-13-5 4-[(1-isopropyl-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]piperidine 
• 122-78-1 phenylacetaldehyde 
• 1327056-67-6 C₂₃H₃₄N₂O₃ 
• 1344029-05-5 C₁₂H₁₇N*ClH 

Relevant articles and documents

Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4- tetrahydroisoquinoline derivatives as novel antihypertensive agents

A series of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized and their bradycardic activities were evaluated in isolated guinea pig right atria. Structure-activity relationship studies revealed that the introduction of an appropriate substituent and its position on the 1,2,3,4-tetrahydroisoquinoline ring are essential for potent in vitro activity. Furthermore, the tether between the piperidyl moiety and the terminal aromatic ring is important for potent antihypertensive activity. Oral administration of 6-fluoro-1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3, 4-tetrahydroisoquinoline (3b) to spontaneously hypertensive rats (SHR) elicited antihypertensive effects without inducing reflex tachycardia, which is often caused by traditional L-type Ca2+ channel blockers.